凯升控股(00102.HK)「二供三」未获足额认购 包销商太阳城(01383.HK)增持至69.66%
凯升控股(00102.HK)公布,「二供三」供股获25.13%有效接纳,余下未认购股份已由包销商履行包销责任。
太阳城(01383.HK)通过作为凯升的包销商,由凯升供股前持有约24.74%股权,增持至约69.66%。此後,凯升的财务业绩将以太阳城之附属公司入账,并将并入太阳城的综合财务报表。
供股所得款项净额为16.18亿元,其中52.3%用於认购事项;37.1%用於水晶虎宫殿(Tigre de Cristal)第二期项目开发;10.6%用於一般营运资金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.